Results 51 to 60 of about 46,872 (214)

SGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis

Endocrine and Metabolic Science, 2021
Background: Sleep disordered breathing (SDB) has a close association with diabetes, especially in obese patients. The use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with diabetes with SDB is a debate with conflicting evidence.
Tanveer Mir, Hassan Bin Atique, Neelambuj Regmi, Yasar Sattar, Saira Sundus, Sabah Ambreen, Prateek Lohia, Waqas T. Qureshi, Ayman Soubani   +8 more
doaj   +1 more source

Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials [PDF]

, 2016
Aims/hypothesis By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium–glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients ...
Del Gobbo, Liana Christine, Li, Yufeng, Song, Yiqing, Tang, Huilin, Zhai, Suodi, Zhang, Jingjing, Zhang, Xi   +6 more
core   +3 more sources

Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation

Frontiers in Pharmacology
Coronary microvascular disease (CMVD) has emerged as a new target for the occurrence and development of heart failure treatment. Various indicators such as Index of Microvascular Resistance, Coronary Flow Reserve, Microvascular Resistance Reserve ...
Shaoxin Chen, Weiqian Ou, Shuguang Gan, Lixian Chen, Baohua Liu, Zhenhong Zhang   +5 more
doaj   +1 more source

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials [PDF]

, 2016
SCI(E)PubMedLETTERyiqsong@iu.edu8E123 ...
Li, Dandan, Song, Yiqing, Tang, Huilin, Wang, Tiansheng, Zhai, Suodi   +4 more
core   +2 more sources

The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis

Cardio-Oncology
Background The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on reducing cardiovascular events in different subgroups of diabetic patients are under investigation. The current systematic review and meta-analysis investigated the effects of
Tara Reshadmanesh, Reza Mohebi, Amir Hossein Behnoush, Azadeh Reshadmanesh, Amirmohammad Khalaji, Mitra Norouzi, Elmira Javanmardi, Reza Pishdad, S. Reza Jafarzadeh, Elina Ghondaghsaz, Sandra Chaparro   +10 more
doaj   +1 more source

Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. [PDF]

, 2019
学位記番号 ...
Shibusawa, Ryo, シブサワ, リョウ, 澁澤, 良   +2 more
core  

Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report [PDF]

, 2020
Introduction: With the incredibly high incidence of Type 2 Diabetes in the current population of emergency department patients, it is critical for clinicians to understand the possible complications of the treatment of this disease.
Ault, Brian, Bonney, Caitlin, Earle, Matthew   +2 more
core  

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]

, 2016
Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes.Systematic review and meta-analysis.
A Berhan, A Lewin, A Liakos, A Patel, AK Singh, B Bode, B Bode, B Neal, B Zinman, C Mathieu, C Sonesson, C Triplitt, Cathy Bennett, CJ Bailey, CJ Bailey, CJ Bailey, CS Kovacs, CS Kovacs, D Moher, D Vasilakou, DS Shyangdan, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, F Zaccardi, Filip K. Knop, FJ Lavalle-Gonzalez, G Guyatt, G Musso, G Schernthaner, H Liu, H Storgaard, H Storgaard, Heidi Storgaard, HJ Lambers Heerspink, HU Haering, HU Haring, HU Haring, IM Stratton, J Bolinder, J Bolinder, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Yoon, JF List, JH Wu, JP Wilding, JP Wilding, JP Wilding, JP Wilding, K Damman, K Kaku, K Kaku, K Stenlof, K Stenlof, K Strojek, K Strojek, L Ji, L Merker, LA Leiter, LA Leiter, LA Leiter, Lise L. Gluud, M Laakso, M Ridderstrale, M Ridderstråle, M Roden, M Sarnak, MA Nauck, MA Nauck, Magnus F. Grøndahl, MH Ahmed, Mikkel B. Christensen, N Inagaki, Noel Christopher Barengo, O Ljunggren, P Gaede, P Jose, RA DeFronzo, RR Henry, RR Holman, S Del Prato, S Goring, S Kalra, S Matthaei, S Matthaei, S Ross, SA Jabbour, SE Inzucchi, SE Kahn, T Forst, T Kadowaki, Tina Vilsbøll, W Duckworth, WL Baker, WT Cefalu, WT Cefalu, Y Yilmaz   +103 more
core   +3 more sources

Possible renoprotective mechanisms of SGLT2 inhibitors

Frontiers in Medicine, 2023
Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor in patients with chronic kidney disease reduces the renal risk independent of changes in blood glucose concentrations and blood pressure. However, the precise mechanism responsible for this SGLT2 inhibitor-induced renoprotective effect is unclear.
Nishiyama, Akira, Kitada, Kento
openaire   +3 more sources

Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis

Frontiers in Cardiovascular Medicine
BackgroundThe effectiveness and safety of a novel class of hypoglycemic medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors have not been completely established in relation to acute heart failure (AHF).
Jingjin Hou, Li Ren, Qingbin Hou, Xiaodong Jia, Zhu Mei, Jiaxin Xu, Zheming Yang, Yiming Li, Chenghui Yan   +8 more
doaj   +1 more source